- Home
- ALF vs XOMA Comparison
ALF vs XOMA Comparison
Compare ALF & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- XOMA
- Stock Information
- Founded
- ALF 2024
- XOMA 1981
- Country
- ALF United States
- XOMA United States
- Employees
- ALF N/A
- XOMA N/A
- Industry
- ALF
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ALF
- XOMA Health Care
- Exchange
- ALF NYSE
- XOMA Nasdaq
- Market Cap
- ALF 379.1M
- XOMA 330.2M
- IPO Year
- ALF 2024
- XOMA N/A
- Fundamental
- Price
- ALF $10.51
- XOMA $27.64
- Analyst Decision
- ALF
- XOMA Strong Buy
- Analyst Count
- ALF 0
- XOMA 2
- Target Price
- ALF N/A
- XOMA $69.50
- AVG Volume (30 Days)
- ALF 74.7K
- XOMA 86.1K
- Earning Date
- ALF 01-01-0001
- XOMA 08-12-2025
- Dividend Yield
- ALF N/A
- XOMA N/A
- EPS Growth
- ALF N/A
- XOMA N/A
- EPS
- ALF 0.37
- XOMA N/A
- Revenue
- ALF N/A
- XOMA $42,909,000.00
- Revenue This Year
- ALF N/A
- XOMA $70.91
- Revenue Next Year
- ALF N/A
- XOMA $14.00
- P/E Ratio
- ALF $28.31
- XOMA N/A
- Revenue Growth
- ALF N/A
- XOMA 638.41
- 52 Week Low
- ALF $9.96
- XOMA $18.35
- 52 Week High
- ALF $10.64
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- XOMA 59.23
- Support Level
- ALF N/A
- XOMA $26.10
- Resistance Level
- ALF N/A
- XOMA $28.70
- Average True Range (ATR)
- ALF 0.00
- XOMA 1.38
- MACD
- ALF 0.00
- XOMA 0.13
- Stochastic Oscillator
- ALF 0.00
- XOMA 79.17
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.